Biohaven Ltd. (BHVN) Stock Analysis

Q: What is the BHVN stock price target?

Take-profit $19.59 (+130.7% upside). Prior stop was $8.18.

Q: Is BHVN overvalued or undervalued?

Biohaven Ltd. trades at a P/E of N/A (forward -4.3). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about BHVN?

25 analysts cover BHVN with a consensus score of 4.0/5. Average price target: $22.

Falling Knife setup

SellModerate ConfidenceUpdated 1 days ago (May 19, 2026, 7:01 AM ET)

Healthcare · Biotechnology

Sell if holding. Engine safety override at $8.57: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 8.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 1.78; Below-average business quality.

$8.57+130.7% A.UpsideScore 4.7/10#120 of 157 Biotechnology

QualityF-score2 / 9FCF yield-29.68%

Stop $8.18Target $19.59(analyst − 10%)A.R:R 8.7:1

Analyst target$21.76+154.0%17 analysts

$19.59our TP

$8.57price

$21.76mean

$50

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Recent Developments — Biohaven Ltd.

Latest news

Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $18 — benzinga May 13, 2026 neutral
RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $22 — benzinga May 5, 2026 positive
Biohaven Files Prospectus For Offering Mixed Shelf; Terms Undisclosed — benzinga May 4, 2026 neutral
Biohaven Q1 Adj. EPS $(0.69) Beats $(0.78) Estimate — benzinga May 4, 2026 positive

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-4.3

Mkt Cap$1.3B

EV/EBITDA-2.0

Profit Mgn0.0%

ROE-333.0%

Rev Growth—

Beta3.31

DividendNone

Rating analysts25

Quality Signals

Piotroski F2/9

Options Flow

P/C1.78bearish

IV95%elevated

Max Pain$5-41.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.415%0.21

Growth5.015%0.75

Momentum2.210%0.22

Sentiment7.710%0.77

Insider Activity5.910%0.59

Peer Rank2.510%0.25

Technical Setup6.55%0.33

Risk Profile1.15%0.06

Catalyst4.45%0.22

Overall (Σ contributions)4.74

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Volatile — 7.8% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Implied Vol

0.0

Beta

0.0

Short Interest

1.4

Put Call

1.4

Debt Equity

2.8

Max Pain Risk

3.0

High short interest justified: 21%Elevated put/call: 1.78High IV: 95%Above max pain $5

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Moat

3.2

Current Ratio

5.6

Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv

1.0

Ma Position

1.0

Macd

1.3

Rsi

3.5

Volume

4.1

Volume distribution (falling OBV)Below 200-MA, MA slope -5.2%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Value Rank

5.0

Growth Rank

5.0

GatesMomentum 2.2<4.5Death cross (50MA < 200MA)A.R:R 8.7 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 83d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive

RSI

36 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $8.43Resistance $10.97

Price Targets

$20

A.Upside+128.6%

A.R:R8.7:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)

! Momentum score 2.2/10 — below 4.5 minimum

! Death cross — 50-day MA below 200-day MA

Earnings

2/4 beats

Next Earnings2026-08-10 (83d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is BHVN stock a buy right now?

Sell if holding. Engine safety override at $8.57: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 8.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 1.78; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Prior stop was $8.18. Score 4.7/10, moderate confidence.

What is the BHVN stock price target?

Take-profit target: $19.59 (+130.7% upside). Prior stop was $8.18. Stop-loss: $8.18.

What are the risks of investing in BHVN?

Quality below floor (1.4 < 4.0).

Is BHVN overvalued or undervalued?

Biohaven Ltd. trades at a P/E of N/A (forward -4.3). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about BHVN?

25 analysts cover BHVN with a consensus score of 4.0/5. Average price target: $22.

What does Biohaven Ltd. do?Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments...

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.